Coherus Biosciences
NASDAQ: CHRSRedwood City, US · Founded 2010 · Delaware corporation · 4 known investors
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
BiotechHealthtechMedical Devices
Founders & leadership
Coherus Biosciences was founded in 2010 by Dennis M. Lanfear and Denny Lanfear.
DM
Dennis M. LanfearCo-founder
DL
Denny LanfearinChairman, Founder, and CEO of Coherus Oncology
AC
Alan C. HermanExecutive
JV
Jean-Frederic Viret, Ph.D.Executive
PK
Peter K. Watler, Ph.D.Executive
BK
Barbara K Finck, M.D.Named on SEC filing
SE
Stuart E. Builder, Ph.D.Named on SEC filing
JM
John Michael Lazarus, M.D.Named on SEC filing
GK
Graham K. Crooke, M.D.Named on SEC filing
Board
AJ
Ali J. SatvatBoard director
JI
James I. Healy, M.D., Ph.D.Board director
MW
Mats WahlstromBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$85.3M disclosed across 4 rounds · 2011–2017
▶$6.8MraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$6.8MraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- V. Bryan LawlisDirector
- Mats WahlstromDirector
- Dennis M. LanfearExecutive Officer, Director
- Barbara K. Finck, M.D.Executive Officer
- Peter K. Watler, Ph.D.Executive Officer
- August J. Troendle, M.D.Director
- Alan C. HermanExecutive Officer
- Jean Frederic Viret, Ph.D.Executive Officer
- James I. Healy, M.D., Ph.D.Director
- Christos RichardsDirector
- Mary T. SzelaDirector
- Ali J. SatvatDirector
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedSep 2015 · 1 investors · Other Health CareRule 506(b)
▶$10MraisedSep 2015 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Barbara K Finck, M.D.Executive Officer
- Ali J. SatvatDirector
- Mats WahlstromDirector
- Alan C. HermanExecutive Officer
- Dennis M. LanfearExecutive Officer, Director
- Jean-Frederic Viret, Ph.D.Executive Officer
- Christos RichardsDirector
- Mary T. SzelaDirector
- August J. Troendle, M.D.Director
- V. Bryan Lawlis, Ph.D.Director
- Peter K. Watler, Ph.D.Executive Officer
- James I. Healy, M.D., Ph.D.Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$55.6MraisedJun 2014 · 35 investors · Other Health CareRule 506(b)
▶$55.6MraisedJun 2014 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- J. Michael Lazarus, M.D.Director
- Alan C. HermanExecutive Officer
- Barbara K. Finck, M.D.Executive Officer
- George G. MontgomeryExecutive Officer
- Christos RichardsDirector
- Dennis M. LanfearExecutive Officer, Director
- Mats WahlstromDirector
- Ali J. SatvatDirector
- James I. Healy, M.D., Ph.D.Director
- August J. Troendle, M.D.Director
- S. Edward TorresDirector
- Offering amount
- $65.6M
- Amount sold
- $55.6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$12.9MraisedJan 2012 · 15 investors · Other Health CareRule 506(b)
▶$12.9MraisedJan 2012 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stuart E. Builder, Ph.D.Director
- Christos RichardsDirector
- John Michael Lazarus, M.D.Director
- Dennis M. LanfearExecutive Officer, Director
- August J. Troendle, M.D.Director
- Mats WahlstromDirector
- Graham K. Crooke, M.D.Director
- Offering amount
- $14.3M
- Amount sold
- $12.9M
- Minimum investment
- $1
- First sale
- Jul 2011
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAgenus53 shared keywords
Amicus Therapeutics44 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Seeking Alpha41 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Robinhood40 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Coherus Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Coherus Biosciences do?
- Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
- Who founded Coherus Biosciences?
- Coherus Biosciences was founded by Dennis M. Lanfear, Denny Lanfear in 2010.
- Who are Coherus Biosciences's investors?
- Coherus Biosciences's investors include F-Prime Capital, HEALTHCARE ROYALTY PARTNERS, Sofinnova Ventures, Venrock.
- How much funding has Coherus Biosciences raised?
- Coherus Biosciences has disclosed $85.3M raised across 4 rounds.
- Where is Coherus Biosciences headquartered?
- Coherus Biosciences is headquartered in Redwood City, US.